European Patent Granted Covering INmune Bio's XPro1595

European Patent Granted Covering

INmune Bio's XPro1595

JOLLA, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, "Company"), a clinical-stage

immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, announced

today that the European Patent Office (EPO) has granted EP Pat. No. 2,892,547, titled "A DOMINANT NEGATIVE TNF-ALPHA INHIBITOR

FOR USE IN TREATING NEUROLOGICAL DISORDERS OF THE CNS," which covers XPro1595 and its peripheral administration for treating

Alzheimer's Disease and other diseases of the CNS. The patent, which is set to expire in 2033, is owned by Xencor, Inc. and

is licensed exclusively to INmune Bio.

patent memorializes the discovery that XPro1595 crosses the blood brain barrier in therapeutically-significant quantities, which

provides for a less invasive peripheral administration of the drug, as opposed to central administration to the CNS," said

Joshua Schoonover, Assoc. General Counsel of INmune Bio. "As a result of this patented discovery, XPro1595 is distinguished

as a next generation anti-TNF therapeutic having properties that are advantageous for treating neuroinflammation."

Bio CEO, RJ Tesi, added: "People from many countries in Europe suffer from a high prevalence of Alzheimer's

disease and other neurologic diseases associated with neuroinflammation. Data from our Phase I trial in AD suggests Xpro1595 may

attenuate neuroinflammation in parts of the brain that are clinically relevant. This European patent gives us the freedom to further

develop XPro1595 for the treatment of neurologic diseases in this important market."

patent comes shortly after INmune Bio's announcement of data showing Xpro1595 decreases neuroinflammation in patients

with Alzheimer's disease. The data shows XPro1595 reduced neuroinflammation by an average of 40.6% in the arcuate

fasciculus, a brain fiber pathway important for language and short-term memory. A Key Opinion Leader Webinar on XPro1595

Phase 1b interim data of neuroinflammation in patient with Alzheimer's Disease can be seen by clicking here.

is a next-generation inhibitor of tumor necrosis factor (TNF) that acts differently than currently existing TNF inhibitors in that

it neutralizes soluble TNF (sTNF) without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro1595 could have beneficial

effects in patients with Alzheimer's disease by decreasing neuroinflammation. For more information about the importance of

targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit this section

of the INmune Bio's website.

About INmune Bio, Inc.

Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target

the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative

technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases.

DN-TNF is currently being developed for COVID-19 complications (Quellor ), cancer (INB03 ), Alzheimer's (XPro595),

and NASH (LIVNate ). The Natural Killer Cell Priming Platform includes INKmune aimed at priming the patient's

NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio's product platforms utilize a precision

medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn

more, please visit www.inmunebio.com.

Forward-Looking Statements

trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this

press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private

Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical

facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.

Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.

Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking

statements as a result of these risks and uncertainties. INB03 , Quellor , XPro1595, LIVNate , and INKmune

are still in clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any

specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations

include, but are not limited to, risks and uncertainties relating to the Company's ability to produce more drug for clinical

trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and

development, clinical studies and future product commercialization; and, the Company's business, research, product development,

regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more

detail in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report

on Form 10-K, the Company's Quarterly Reports on Form 10-Q and the Company's Current Reports on Form 8-K. The Company

assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after

the date of this release.

David Moss, CFO (858) 964-3720

James Carbonara (646) 755-7412